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Indications and Future Directions
Ashish Castellino and Mohan Kameswaran
Abstract
Approximately one-third of persons over 65 years are affected by disabling 
hearing loss. It is estimated that the number of people with disabling hearing loss 
will grow to 630 million by 2030 and maybe over 900 million by 2050. Deafness 
has significant consequences on many aspects of an individual’s life, including their 
socioeconomic status, mental and physical well-being, educational and employ-
ment opportunities. When congenital or early in the developmental years, deafness 
results in a delay or loss of language acquisition. Deafness can result from damage 
or disease anywhere along the auditory pathway. Hearing prosthetic devices help 
restore hearing and the use of these devices depends on the degree and type of hear-
ing loss. This chapter will give a brief account of the currently available prosthetic 
hearing solutions.
Keywords: auditory brainstem implant, auditory midbrain implant, bone conduction 
implant, cochlear implant, hearing aid, middle ear implant
1. Introduction: the neurosensory problem
The global burden of disabling hearing impairment is estimated at 466  million 
people (6.1% of the world’s population) where 432 million (93%) of these are 
adults (242 million males, 190 million females) and 34 million (7%) children. It is 
estimated that the number of people with deafness will grow to 630 million by 2030 
and maybe over 900 million by 2050 [1].
Hearing impairment has a significant bearing on many aspects of an individual’s 
life, including their socioeconomic status, mental well-being, education and 
employment opportunities. Older people with moderate or more severe hearing 
loss were more likely to feel depressed and suffer with poor mental health [2]. The 
deaf child cannot listen to her or his mother and focus on an activity simultaneously 
since both inputs must be processed visually. In addition, the deaf child is unaware 
of sounds of the outside environment, and thus, is centered on self and own activi-
ties. This has consequences on the child’s development of language, social skills and 
cognition [3].
Hearing impairment results from damage or disease anywhere along the auditory 
pathway. Surgical restoration of hearing involves procedures that range from ossicu-
lar reconstruction to implantation of devices which serve to assist the functioning 
of the auditory pathway. The prosthetic devices currently being used for restoration 
of hearing are classified based on their mode of action in Figure 1.
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2. The auditory prosthetic solutions
The first prosthetic used for the management of deafness on record in human 
history was the Ear Trumpet or Horn. These were funnel shaped devices which 
collected sound waves and led them into the ear, thus strengthening the impact 
of sound energy on the ear drum and improving hearing. The use of these devices 
date back to the 17th century with the earliest description given by the French Jesuit 
priest and mathematician Jean Leurechon in his work “Recreations Mathematiques” 
(1634). Commercial production of these devices began much later in the 1800s and 
many notable personalities of that era including pianist Ludwig van Beethoven are 
known to have used them.
2.1 Candidacy assessment
Hearing impaired individuals usually seek help only when they have reached a 
stage that they can no longer ignore their hearing loss. Often, it is not the individual 
themselves, but the family member/caretaker who notes that the concerned indi-
vidual is struggling with their hearing impairment. In either situation, the pre-
audiometric assessment which involves collection of relevant medical history and 
clinical examination of the hearing-impaired person is an important first step of the 
auditory rehabilitation process. It is important to identify patients in whom medical 
or non-prosthetic surgical management of their hearing loss should be attempted 
prior to dispensing of the hearing device. After the clinical assessment, the candi-
dacy process involves a complete audiological evaluation using the  following tests.
Pure Tone Audiometry (PTA) – This is a subjective test involving hearing 
threshold evaluation in both air conduction and bone conduction.
Speech Audiometry – This test provides information concerning hearing for 
speech, the type and degree of hearing impairment, and to check the reliability of 
the pure tone thresholds.
Brainstem Evoked Response Audiometry (BERA) – This test is an objective 
and non-invasive method of hearing assessment which detects electrical activity 
along the auditory pathway (from inner ear to inferior colliculus) in response to 
sound impulse.
Figure 1. 
Classification of hearing prosthetic devices.
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Oto-Acoustic Emissions (OAE) – This involves recording of a low-level sound 
emitted by the cochlea either spontaneously or evoked by an auditory stimulus thus 
indicating integrity of the outer hair cells of the cochlea.
Cortical Auditory Evoked Potentials (CAEP) – This test is an objective and 
non-invasive assessment of electrical activity from the level of the inferior collicu-
lus to the primary auditory cortex in response to sound stimulus.
Aided Audiometry – This test is similar to PTA but involving the estimation of 
hearing thresholds during the use of a hearing prosthesis.
2.2 The hearing aid (HA)
2.2.1 History
The simplest and most widely used auditory prosthetic solution is the Hearing 
Aid. The first electronic hearing aids in the mid-19th century were large instru-
ments that sat on a table. The subsequent invention of the transistor and miniature 
electron tubes made the hearing aid small enough to fit behind the ear. In the late 
1960s the introduction of minicomputers opened the doors to real-time signal 
processing for people with hearing loss. Although not fast enough, these were 
computer-controlled analog systems which were used for amplification in hearing 
aid devices. In 1975, Daniel Graupe developed the first digital hearing aid in which 
high speed digital-array processors were used. This made it possible to process audio 
signals digitally in real time. Finally, in the early 1980s, the Central Institute of the 
Deaf (CID) developed the first practical wearable digital hearing aid which set 
precedent to the current type of aids in use [4].
2.2.2 Design
The modern digital hearing aid is a marvel of sophisticated engineering and 
miniaturization. The microphone is the first component to receive the sound 
signal and it converts this energy into electricity. These microphones may be 
unidirectional, bidirectional or omnidirectional. A more sophisticated type of 
an omnidirectional microphone is an “adaptive directional microphone” which 
works together with the hearing aid’s noise reduction technology to highlight 
speech sounds and important environmental sounds while suppressing back-
ground noise. These small signals generated by the microphone are sent to the 
amplifier which makes them more powerful. Compression amplifiers are used 
to amplify the signal while avoiding distortion and decreasing its dynamic range 
and can represent sound in either an analogue (mimicking acoustic waveforms) 
or digital (representing signals as a string of numbers) manner. The signal then 
goes through a filter which is used to change the relative amplitude of the high, 
mid and low frequency characteristics of a signal. Thus, the sound signal can be 
altered by the user or clinician to suit the type of hearing loss. Finally, the receiver 
converts this modified and amplified electrical signal back into sound with the 
help of electromagnetism which is similar to how headphones work. The hearing 
aid performs all these functions with the help of electrical power from a detach-
able battery. Based on where they are worn, hearing aids are classified as body 
(pocket aids), spectacle, behind-the-ear (BTE), in-the-ear (ITE), in-the-canal 
(ITC) and completely-in-canal (CIC). BTE are further classified based on location 
of the receiver as receiver-in-the-aid (RITA) where the receiver lies within the 




2.2.3 Mode of action
The primary mode of action of a hearing aid involves amplification of the 
input sound signal accompanied by frequency specific sound signal modulation to 
produce a tailormade output sound signal aimed at supporting the targeted hearing 
impairment. Hearing aid technology has seen rapid growth in the past 50 years and 
these advances can be broadly classified into three generations, all of which are cur-
rently commercially available. The first generation were simple analog hearing aids 
which were adjusted with screwdriver-controlled potentiometer trimmers accord-
ing to the degree of hearing loss. An analog hearing aid consists of a microphone, 
preamplifier, a tone controller (or automatic gain controller - AGC), an amplifier 
and a receiver. In such devices, an acoustic signal is converted by the microphone 
into an electric signal which is amplified by a preamplifier and the frequency is 
shaped by the tone controller. This signal is then again amplified and converted into 
an acoustic output signal by the receiver. These were followed by second genera-
tion analog devices which could be digitally programmed by dedicated devices or 
computers. This involved coding of certain parameters of the analog components 
such as tone control and allowing these settings to be stored in a memory that can 
be modified or retrieved according to user preference. Digital hearing aids, which 
represent the third-generation, differ from the analog devices in that the ampli-
fied electronic signals are converted into digital signals which are processed by the 
Digital Signal Processor (DSP) before being converted back to analog electronic 
signals. Thus, these devices usually have an analog-to-digital converter, a digital 
signal processor and a digital-to-analog converter, of which the latter function is 
often embedded within the receiver in the newer devices. The entire system is built 
on a single integrated circuit that contains all the electronic parts i.e. transistors, 
capacitors and resistors [5].
2.2.4 Contralateral routing of signal (CROS)/binaural CROS (BiCROS)
CROS are hearing aids worn bilaterally where the hearing aid on the affected 
side transmits the acoustic signal to the receiver in a hearing aid worn on the better 
hearing ear. In patients who have hearing loss in the better hearing ear, the hearing 
aid in the better ear can also be used to provide amplification to that ear in addition 
to the CROS input. This configuration is called BiCROS [6].
2.3 The bone conduction device (BCD)
2.3.1 History
In the 1st century, Pliny the Elder, a Roman scientist, was the first to remark 
about the potential of sound conduction through solid bodies. Several centuries 
later, Cardano demonstrated a method by which sound may be transmitted to the 
ear by means of the shaft of a spear held between one’s teeth [7]. About a hundred 
years later, in the 1600s, it was Hieronymus Capivacci, an Italian physician, who 
realized the clinical significance of Cardano’s observations. Using the same experi-
ment he determined that if the patient heard the sound it indicated disease of the 
tympanic membrane, while if the patient could not hear the sound it indicated 
a lesion of the auditory nerve [8]. In 1757, Johann Jorissen, a German physician, 
published the first known dissertation dealing exclusively with hearing through 
teeth. But it was only in 1821, when the first primitive bone conduction device was 
developed by Jean-Marie Gaspard Itard, a French ear specialist who postulated that 
sound was conducted through the bones of the entire skull [9]. Using the concepts 
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of the carbon microphone and the magnetic receiver (earphone) in 1920, Joseph 
Prenn of Boston, patented a mechanical bone-conductive ear [10]. However, it was 
Frederick Kranz of Illinois, who in 1925, patented the first real bone conduction 
vibrator which was handheld initially, and later attached to a headband and set the 
tone for bone conduction technology [11]. With the help of the Sonotone Company, 
Hugo Lieber developed a small wearable bone conduction receiver in 1933 [12]. 
Another idea was to fix the bone conduction device in eye glasses. From the 1960s to 
the 1990s, four different companies – Amplivox, Akumed, Otarion & Oticon made 
bone conduction eyeglasses which became the most widely used bone conduction 
hearing devices of that time. The idea to implant the vibrator into the mastoid 
bone originated in Sweden, after the pioneering work of the anatomist, Per-Ingvar 
Brånemark in bone rheology, where Anders Tjellström fitted the first 3 patients 
with the BAHA implant in 1977 [13].
2.3.2 Design, mode of action & candidacy
Bone conduction devices are prosthetic devices that aid hearing by converting 
sound energy into vibrational energy. The vibrations that are produced are trans-
mitted to the skull bone, and then to the inner ear bypassing a hearing impairment 
in the external or middle ear, thus overcoming the air conduction defect. Below 
is a basic classification of bone conduction devices (BCD) based on their mode of 
action: Direct-drive (sound vibration is sent to bone directly in the presence of a skin 
defect), Skin-drive (where sound vibration is sent to bone via intact skin) & In-the-
mouth (where sound vibration is sent to the teeth). BCDs can also be classified as 
non-implantable (conventional bone conduction devices) and semi-implantable 
devices (where some part of the device is implanted).
The Conventional Skin-Drive Non-Implantable BCDs usually consist of 
a processor attached to soft headbands (softbands), steel spring headbands or 
spectacles. Common drawbacks of these devices are that a high static skin pressure 
is required to transmit the vibrations to the cochlea, leaving the skin compressed for 
prolonged periods, which might lead to discomfort and skin problems. Also, skin 
attenuates the high-frequency sound signal and therefore sound that reaches the 
cochlea has a lower content of high frequencies. These devices are commonly used 
to confirm candidacy before formal implantation of a BCD. Alternatively, they are 
used when surgery is contraindicated or refused. Candidacy requirements for this 
type of BCD include a permanent conductive hearing loss secondary to microtia, 
atresia or syndromic; bilateral mixed hearing loss with bone conduction average of 
35 dB or less and single sided deafness where bone conduction average is 15 dB or 
less in the better ear. There are no age restrictions. Below are some of the common 
conventional skin-drive non implantable BCDs available.
2.3.3 The Cochlear BAHA SoundArc
This is a conventional skin-drive non-implantable BCD that is designed to be 
worn behind the head with the BAHA sound processor attached to the connector 
disc just behind the ear.
2.3.4 The Softband with BAHA processor attached
This is a conventional skin-drive non-implantable BCD that consists of a bone 
conduction processor fitted on a soft headband and is indicated in the pediatric 




2.3.5 The Med-El ADHEAR
This is a conventional skin-drive non-implantable BCD consisting of an adhesive 
adapter which is placed behind the pinna on the mastoid skin and a bone conduc-
tion processor which gets attached to that adapter.
The semi-implantable BCDs have several advantages over the conventional 
BCDs which include a lack of static skin compression and preservation of the high 
frequency signals. These BCDs are further classified as direct-drive percutaneous 
devices, direct-drive active transcutaneous devices (with an implanted transducer) 
and skin-drive passive transcutaneous devices (with an implanted magnet).
The Semi-implantable Direct-drive Percutaneous BCDs involve use of a 
biocompatible osseointegrated implant to which a percutaneous abutment is 
fixed. The sound processor is then clicked on to the abutment to activate hearing. 
The major benefit of these devices is an efficient percutaneous transmission of 
sound vibrations providing maximum amplification. Candidacy requirements for 
this type of BCD include a conductive hearing loss with an air bone gap of more 
than 30 dB; mixed hearing loss with a conductive component more than 30 dB 
and sensorineural component of up to 65 dB HL and single sided deafness where 
bone conduction average is 15 dB or less in the better ear. Suitable for ages 5 years 
and above.
2.3.6 The Cochlear BAHA CONNECT
The BAHA CONNECT system was the first commercially available bone 
conduction device. This direct-drive percutaneous system consists of a titanium 
implant which is osseointegrated into the skull, along with a sound processor 
which transmits these vibrations through a percutaneous abutment which connects 
the sound processor to the implant. The skin is left intact around the abutment 
using ‘Dermalock’ technology. The Cochlear BAHA 5 sound processor features the 
‘BCDrive’ electromagnetic transducer. This transducer creates vibrations that are 
sent through to the cochlea via an abutment in the case of BAHA CONNECT, or 
an implanted and an external magnet in the case of BAHA ATTRACT (described 
later). This sound processor can also be used in the conventional way by con-
necting to either the Softband or the SoundArc. The BAHA 5 System consists of a 
range of sound processors including the BAHA 5 Sound Processor (for up to 45 dB 
SNHL), the BAHA 5 Power Sound Processor (for up to 55 dB SNHL) and the BAHA 
SuperPower Sound Processor (for up to 65 dB SNHL) which address different levels 
of hearing loss.
2.3.7 The Oticon PONTO 4
The Oticon PONTO 4 system is a direct-drive percutaneous device that consists 
of three parts – a 4 mm titanium implant that is surgically implanted into the skull, 
an abutment that is seamlessly placed percutaneously through the skin and a sound 
processor that clicks easily to the abutment and sits discreetly behind the ear. In 
addition to its remarkably small size, the PONTO 4 system also connects wirelessly 
to the internet using an IFTTT network.
The Semi-implantable Skin-drive Passive Transcutaneous BCDs have a 
major advantage in complete elimination of the soft tissue & skin complications 
of a percutaneous abutment but their disadvantages include the large artifact area 
on post-implant MRI scans and the possible dampening of high-frequency sound 
signals through the skin. Candidacy requirements for this type of BCD are similar to 
the direct drive percutaneous BCDs.
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2.3.8 The BAHA ATTRACT
The BAHA ATTRACT system is a skin-drive passive transcutaneous device that 
transmits sound vibrations to the inner ear through a magnetic connection between 
the sound processor and the implant. The magnet which lies on the inside to the skin is 
attached to the underlying skull bone with a screw, and the BAHA sound processor is 
attached to a magnet plate on the skin via a soft pad to equalize the force distribution 
over the attachment surface. This BCD offers the benefit that there is no skin penetrat-
ing abutment, thus providing a good esthetic outcome with no need for daily care.
2.3.9 Medtronic ALPHA 2 MPO
The Medtronic ALPHA 2 MPO system is a skin-drive passive transcutaneous 
device that consists of a surgically implanted internal plate containing two airtight 
sealed magnets and the external digital sound processor coupled to the base plate 
containing twin magnets corresponding to the internal ones. In order to overcome 
the skin problems related to high static skin pressure, it uses a larger surface area so 
that the static force is widely distributed alleviating dermal compression [14].
In Semi-implantable Direct-drive Active Transcutaneous BCDs, the trans-
ducer is implanted in bone under intact skin. Hence, vibrations are transmitted 
directly from the transducer to the skull bone with the elimination of dermal 
impedance. These BCDs are labeled transcutaneous since it is an electromag-
netic signal from the sound processor that is transmitted through the skin to the 
implanted transducer and not sound vibrations. Candidacy requirements for this 
type of BCD are similar to the direct drive percutaneous devices (except for age 
12 years and above for Cochlear OSIA).
2.3.10 The Med-El BONEBRIDGE
The BONEBRIDGE is a direct-drive active transcutaneous system that consists 
of an external audio processor and an internal bone conduction implant. The 
internal component has a receiver coil, a magnet, a demodulator, and a cylindri-
cally shaped bone-conduction floating mass transducer (BC-FMT) secured to 
the bone by two titanium screws. The power to drive the FMT is transmitted 
transcutaneously to the internal coil, processed by the demodulator and then 
relayed to the BC-FMT, which then transduces the signals into mechanical energy. 
Osseointegration of the titanium screws, however, is not thought to be crucial.
2.3.11 The Cochlear OSIA
The OSIA System is a direct-drive active transcutaneous system that uses a 
Piezo-Power transducer which sits within the OSI200 implant, and is positioned 
under the skin to send sound to the cochlea. The OSI200 implant is positioned on 
top of the bone and connected to the osseointegrated BI300 Implant which gives an 
important single-point transmission for sound to the skull. The system has a fitting 
range of 55 dB SNHL. The transducer functions on the principle of the “piezoelec-
tric effect” which is the ability of certain materials to generate vibrations when 
provided with an electrical charge.
2.3.12 In-the-mouth BCD: SoundBite
This in-the-mouth BCD is neither direct-drive nor skin-drive. The vibrations 
are generated by a piezoelectric transducer and are transmitted through the teeth 
Orthotics and Prosthetics
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to the skull. SoundBite by Sonitus was mainly developed for single sided deafness 
patients. A microphone is placed behind the deaf ear and sound is sent wirelessly to 
an in-the-mouth transducer transmitting vibrations to the upper molar teeth. These 
vibrations are transmitted to the skull bone and received by the healthy cochlea. 
This device is currently only available for investigational use for the management of 
single sided deafness and is not available commercially [15].
2.4 The active middle ear implant (AMEI)
2.4.1 History
Alvar Wilska, a Finnish physiologist, is credited with the first attempt at 
mechanical stimulation of the auditory system with the help of an electromagnetic 
driver. In 1935, he sprinkled iron filings on to the tympanic membrane of a patient 
lying on his side and placed a ear-phone over the man’s ear that produced no sound, 
but an electromagnetic signal, and the patient reported hearing. Subsequently, in 
1959, Rutschmann devised a method of fixing a tiny permanent magnet to the tym-
panic membrane at the umbo with water soluble glue. By introducing an alternating 
current he produced pure tones in the range of 2 kHz to 10 kHz [16]. In 1973, Goode 
and Glattke refined this work by introducing an electromagnetic coil on the post-
auricular skin to drive the magnet fixed on the umbo. Heide reported an important 
modification to these previous studies in 1988, by replacing the postauricular trans-
ducer with an in-the-canal electromagnetic induction coil located millimeters from 
a magnet fixed at the umbo [17]. Prior to this in 1986, Maniglia at Case Western 
Reserve University had already begun investigating one of the first contactless 
electromagnetic based middle ear implant systems. In that same year, Kartush and 
Tos, at the Michigan Ear Institute, collaborated with Smith & Nephew Richards, to 
create an electromagnetic-based partially implantable middle ear device that used 
an in-the-canal electromagnetic coil with a custom ear mold housing [18]. The use 
of piezoelectric crystals in middle ear implants became evident in 1984, when the 
RION device became the first commercially approved piezoelectric-based middle 
ear device to be implanted. Since this time, several additional middle ear implants 
have used this technology, including the Impex TICA and the Envoy Esteem. 
This was roughly a century after Piezoelectricity was first discovered by Jacques 
and Pierre Curie in 1880 after observing that certain solid substrates develop an 
electrical charge proportional to an applied mechanical stress. In 1996, Geoffrey 
Ball pioneered development of the VIBRANT SOUNDBRIDGE which became the 
first FDA approved Active Middle Ear Implant (AMEI) system for implantation in 
patients with SNHL, receiving approval in August 2000 [19].
2.4.2 Design, mode of action & candidacy
These can be classified as totally implantable if all these parts are beneath the 
skin or partially implantable if only the receptor and transducer are implanted 
beneath the skin. Depending on the type of energy the transducer utilizes, MEI 
are classified as: Piezoelectric – when energy is transmitted to a piezoelectric 
crystal, which deforms it or changes its volume generating a vibratory signal; 
Electromagnetic – when energy is transmitted to a coil that generates an electromag-
netic field that causes a magnet located close to the ossicular chain or the inner ear 
to vibrate and thus produce a vibratory signal; or; Electromechanical – which are 
similar to the electromagnetic implants but the coil and magnet are closely related 
to each other and the ossicular chain [20]. The main advantages of the AMEI over 
hearing aids is that they induce direct mechanical vibration of the ossicular chain or 
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(and) the intracochlear fluids and thus generate greater functional gain, especially 
over the acute frequencies, with less distortion and feedback, increasing spoken-
word discrimination. In terms of subjective results, patients report better intelligi-
bility and quality of sound and a more natural perception of their own voice than 
obtained with hearing aids [21].
2.4.3 The Med-El VIBRANT SOUNDBRIDGE
The VIBRANT SOUNDBRIDGE (VSB) is currently the most widely implanted 
middle ear device worldwide. This AMEI consists of an externally worn proces-
sor that contains the microphone, electronic signal processor and battery and an 
implantable part called the Vibrating Ossicular Prosthesis (VORP). This VORP 
contains a magnet (that enables the external part to be coupled), a receiver unit, 
a demodulator (that filters the signal received), a conductor link for the electrical 
signal and a floating mass transducer (FMT). Sound signal received by the external 
audio processor is transmitted transcutaneously to the implanted device generat-
ing vibratory movements of the FMT and conduction of sound to the inner ear. 
The FMT coupled to the Incus is the original indication devised for patients with a 
healthy middle ear and moderate–severe sensorineural hearing loss in the higher 
frequencies with a discrimination >50% at conversational intensity who were not 
satisfied with their hearing aid or who had repeated external otitis. The VSB is 
the only AMEI approved for use in children since 2009. It is indicated in children 
with external auditory canal atresia and bilateral malformations of the ossicular 
chain who have sensorineural conductive or mixed hearing loss and meet the same 
audiological criteria as for adults.
2.4.4 The Cochlear CARINA
This is a totally implantable AMEI which consists of two parts, the electronic 
capsule that contains the microphone, the batteries, the digital processor and the 
connector, and the middle ear transducer that contains the receiver unit and the 
electromechanical transducer. All these parts are placed beneath the skin with no 
need for externally worn processors. This AMEI is indicated for adults with moder-
ate to severe SNHL with a hearing threshold between 30 and 85dBHL especially in 
the higher frequencies.
2.4.5 CODACS (direct acoustic Cochlear implant)
The CODACS implant is a semi-implantable device that is still in a preliminary 
phase and is gradually being used in some European centers. This AMEI is indicated 
for patients with severe to profound mixed hearing loss due to otosclerosis either as 
a primary indication or after stapedial surgery has failed.
2.4.6 The envoy ESTEEM implant
The Envoy ESTEEM implant is a fully implantable device which is indicated in 
patients with moderate to severe and severe sensorineural hearing loss. The system 
uses two piezoelectric transducers (PZTs). Sound is received via a PZT sensor that 
picks up eardrum vibrations and transforms them into an electric signal. This signal 
is filtered, modified, amplified and transferred to a PZT driver which mechanically 
drives the stapes thus conducting sound to the inner ear. The sound processor also 
contains a power source, which is an implantable lithium iodide battery [22]. For 
candidacy, hearing thresholds should be stable and between 35 and 85dBHL for 
Orthotics and Prosthetics
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audiometric frequencies of 500-4000 Hz with a word recognition score of 40% or 
greater. It is currently indicated only in patients older than 18 years.
2.5 The Cochlear implant (CI)
2.5.1 History
The history of the cochlear implant dates back to the first attempts at electrical 
hearing. The Italian scientist Alessandro Volta (1800) was the first to demonstrate 
that electric stimulation could directly evoke auditory sensations in humans when 
he invented the battery [23]. However electric stimulation of the auditory system 
was not subsequently reported for another 150 years until modern electronic 
technology appeared. SS Stevens and his colleagues conducted a series of studies 
to re-examine the electric stimulation of hearing using vacuum based tube oscilla-
tors and an amplifier, a copper wire serving as an electrode. They identified three 
mechanisms that were responsible - the first mechanism was called an “electrome-
chanical effect” by Kiang & Moxon in 1972 in which electrical stimulation causes 
the hair cells in the cochlear to vibrate, resulting in a perceived tonal pitch at the 
signal frequency it was acoustically stimulated; the second mechanism occurs 
due to the tympanic membrane’s conversion of the electric signal into an acoustic 
signal, resulting in a tonal pitch perception but at the doubled signal frequency; 
while, the third mechanism is due to direct electric activation of the auditory nerve. 
However, it was Andreev who first gave direct evidence of electric stimulation of 
the auditory nerve when hearing sensations were reported with electric stimulation 
in a deaf patient whose middle and inner ears were damaged [24]. The modern era 
of cochlear implants began when Djourno and Eyries successfully performed the 
electric stimulation of hearing in two deafened patients in 1957 [25]. Their success 
led to a frenzied increase in attempts to restore hearing to deaf people on the US 
west coast in the 1960 and 1970s. Although their methods were crude, these stud-
ies identified critical problems and limitations that needed to be considered and 
overcome for successful implementation of electric hearing. In 1984, the House 3 M 
single-electrode implant became the first Food and Drug Administration (FDA) 
approved device. This was followed by the Ineraid or Symbion device developed by 
the University of Utah, the Laura device developed by the University of Antwerp, 
and the Digisonix MX20 developed by the MXM laboratories in France. These 
devices were later phased out and are no longer commercially available [26]. At 
present, there are three major cochlear implant manufacturers including Med-El 
Corporation, Austria; Cochlear Corporation, Australia and Advanced Bionics, USA. 
In addition to its design, implantation criteria have evolved over the past decades. 
Niparko provides a detailed account of these evolving criteria in patient selection 
as well as the surgical, cost-utility, educational, pre and post-operative issues in 
cochlear implants [27]. Most notably, the audiological criteria for cochlear implan-
tation has relaxed from bilateral total deafness (<110 dB HL) in the early 1980s to 
severe hearing loss (>70db HL) in the 1990s, and then to current suprathreshold 
speech based criteria (<50% open-set sentence recognition with properly fitted 
hearing aids).
2.5.2 Design, mode of action & candidacy
The essential components of a cochlear implant are as follows – a microphone 
converts sound into an electrical signal for input to the speech processor. The pro-
cessor transforms this electrical input into a set of stimuli for the implanted array of 
electrodes. These stimuli are sent to the electrodes via a transcutaneous link which 
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involves encoding of the stimulus information for efficient radiofrequency trans-
mission from an external transmitting coil to an internal (implanted) receiving coil. 
The signal received by the internal coil is decoded to specify the electrical stimuli 
for the electrode array. These electrical stimuli that stimulate the hair cells have 
signal characteristics which determine the sound quality of the perceived stimulus.
2.5.3 Med-El SYNCHRONY CI
The SYNCHRONY cochlear implant system consists of the SYNCHRONY 2 
cochlear implant with the Sonnet 2 BTE or Rondo 2 sound processor. The implanted 
device has a removable magnet that may be temporarily taken out by a cochlear 
implant surgeon in the event that the MRI (up to 3.0 Tesla) is needed for the head. 
Med-El offers the largest selection of electrode options within the cochlear implant 
industry. Traditional electrode options include the standard array, medium array, 
compressed array and split electrodes array. The newest options include the FLEX 
24, 28 and FLEX SOFT electrodes. The Sonnet 2 is a redesigned BTE sound proces-
sor for greater ease of use, better esthetics and improved reliability. It recognizes 
the ambient environment or scene and automatically adjusts settings to match it. 
The Rondo 2 is a unique sound processor option different from the Sonnet 2. It 
has innovative wireless charging, simple on/off button and automatically controls 
volume level for the recipient with up to 18 hours of battery life. The device is small 
and compact and sits on the head, just behind and above the ear and more comfort-
able to wear with glasses as compared to any BTE system.
2.5.4 The advanced bionics NAIDA CI
The HiRes Ultra 3D cochlear implant has a multi-magnet assembly which auto-
matically provides alignment to the 3D MRI field, allowing adult and pediatric users 
to undergo 3.0 Tesla MRIs safely, without any preparation surgery or head bandag-
ing. This unique magnet assembly is composed of four rotatable magnets encased 
in a revolving disc allowing alignment with the 3D MRI field. There is no need for 
head bandaging or possible surgical removal of the magnet. The electrode array 
options in Advanced Bionics include the HiFocus Mid-Scala electrode array – which 
is designed to lie in the center of the scala tympani in order to remain reasonable 
proximal to the modiolus (and cochlear neural elements) while not making physical 
contact with the delicate cochlear structures necessary to maintain residual hear-
ing; and, the HiFocus Slim J electrode array – which is designed to be placed in the 
scala tympani toward the lateral cochlear wall away from the cochlear structures. 
The Naída CI Connect is a design-integrated solution which turns the Naída CI Q90 
sound processor into a Bluetooth headset which allows for hands-free calling and 
direct audio streaming from any compatible device.
2.5.5 Cochlear nucleus PROFILE PLUS CI
Built on the same design of the predecessor Profile series, Profile Plus provides 
easier access to MRI at 1.5 Tesla and 3.0 Tesla without the need for compression or 
magnet removal. The Profile Plus is available with the following electrode types: 
Slim Modiolar (CI632), Slim Straight (CI622), Slim 20 (C624) & Contour Advance 
(CI612). The Contour advance electrode array has a perimodiolar design and a soft 
tip which is designed to reduce trauma to the delicate cochlear structures during 
insertion using the Advanced Off-Stylet (AOS) technique. The Straight array is 
recommended for patients with cochlear anomalies like the common cavity and in 
situations where there is fibrous tissue growth in the cochlea (bacterial meningitis). 
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The Cochlear NUCLEUS 7 Sound Processor is the smallest and lightest BTE hearing 
solution with built-in connectivity featuring direct streaming with a compatible 
Apple and Android device without attaching anything to the sound processor. The 
Kanso 2 Sound Processor is the smallest and lightest off-the ear solution available 
that has built-in technology offering direct streaming, control and connectivity 
with a compatible device.
2.5.6 Candidacy
Current clinical guidelines for implant candidacy represent a composite assess-
ment of the individual’s age (>12 months), hearing loss history, aided and unaided 
audition (comprehensive audiometric assessment), the socioeconomic and family 
support of the patient likely to influence the use of the device; and an awareness 
of potential benefits and constraints of current implantable technologies. These 
can be estimated via high resolution imaging complemented by thorough audio-
metric assessment and a multidisciplinary team-based preoperative counseling or 
intervention.
2.6 The auditory brainstem implant (ABI)
2.6.1 History
Hitselberger and House performed the first implantation of an ABI in 1979 
[28]. It was a single spherical electrode implanted adjacent to the cochlear 
nucleus following removal of bilateral vestibular schwannomas of a patient with 
Neurofibromatosis Type 2 (NF2). In 1992, Cochlear Ltd. in conjunction with the 
Huntington Medical Research Institute developed the first multichannel electrode 
array devices which have, in most cases, provided patients with greater benefits 
than the earlier devices [29].
2.6.2 Design, mode of action & candidacy
Although in the earlier years the most frequent indication of an ABI was NF2, 
a genetic disorder with an autosomal dominant inheritance pattern in which the 
patient develops benign vestibular schwannomas on both eighth cranial nerves; in 
recent years, the indications for the ABI have expanded to include bilateral cochlear 
ossification, unilateral vestibular schwannoma with deafness in the contralateral 
ear that is not amenable to a cochlear implant, congenital cochlear nerve aplasia 
or hypoplasia, complete cochlear ossification, malformation of the inner ear, and 
bilateral traumatic avulsions or absence of the cochlear nerve [30]. The current ABI 
system utilizes 12 platinum disk electrodes aligned on a flexible silicone and poly-
ester mesh backing for implantation into the lateral recess of the fourth ventricle on 
the cochlear nucleus of the brain. This bypasses a non-functioning auditory nerve 
and allows signals to be sent to the brain.
2.7 The auditory midbrain implant (AMI)
2.7.1 History
The first reported attempt at stimulation of the inferior colliculus (IC) of 
the midbrain for hearing restoration was in 1962 by Simmons and colleagues at 
Stanford University during a tumor removal operation [31]. The second attempt at 
stimulating the surface of the IC happened much later in 2005 and involved using 
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an ABI array in a NF2 patient to assess if the limited performance with cochlear 
nucleus stimulation secondary to tumor related damage could be overcome by stim-
ulation in a higher auditory center and they were successful in eliciting a response 
at much higher thresholds than what is used in cochlear nucleus stimulation [32]. 
In 2006, Thomas and Minoo Lenarz at the Hannover Medical University developed 
the first human prototype Auditory Midbrain Implant (AMI) array for penetrating 
stimulation across the tonotopic gradient of the central nucleus of the IC [33].
2.7.2 Design, mode of action & candidacy
The AMI is a type of central auditory prosthesis that targets midbrain regions 
beyond the cochlear nucleus, particularly the central nucleus of the Inferior 
Colliculus (ICC). There are several properties of the ICC that make it a logical 
choice for a prosthetic target including being a converging center for almost all 
ascending auditory projections, possessing tonotopic anatomical organization in 
addition to spatial organization for speech perception. The Cochlear Ltd. CI array 
was reduced in dimensions to create an AMI array that was small enough to insert 
into the ICC with the goal of stimulating its different layers. The AMI electrode 
array measures 6.4 mm long and a diameter of 0.4 mm and possesses 20 linearly 
spaced platinum ring electrodes. A distal Dacron mesh prevents over insertion of 
the electrode into the ICC during implantation and anchors the electrode array 
onto the surface of the inferior colliculus to minimize movement after positioning. 
The other components of the AMI system are similar to the Cochlear NUCLEUS CI 
system consisting of behind-the-ear microphone and processor that transmits the 
electromagnetic signals to the receiver stimulator implanted under the skin.
2.8 The vestibular implant
2.8.1 History
Vestibular disorders are widely prevalent and can cause significant morbidity in 
the form of incapacitating symptoms, missed work days and even the inability to 
leave one’s home. Advancements in the treatment of vestibular disorders are lacking 
and the surgical treatment of vestibular disorders has remained unchanged in the 
past two decades. Over the same duration, neural prosthesis have been developed 
that substitute one modality for another in order to restore a missing sense. Current 
research in vestibular neurostimulation has finally made possible the clinical reality 
of treating a wide range of vestibular disorders with electric stimulation.
2.8.2 Design, mode of action & candidacy
Vestibular implantation is useful in recurrent acute vertigo attacks (in which 
central compensation does not occur), for chronic bilateral hypofunction and for 
Meniere’s disease, in which vertiginous attacks may be precipitated by an acute loss 
of vestibular tone. These are ideal candidates for a “pacemaker”-style vestibular 
implant that replaces the missing neural impulses during attacks. This implant 
bypasses the vestibular end organs to directly stimulate the vestibular nerve. The 
goal of vestibular implantation is to provide vestibular functionality and or reduce 
symptomatology by programmed stimulation of the vestibular nerve. This device 
consists of a modified Nucleus Freedom system. The receiver-stimulator has a 
modified trifurcating array of 9 electrodes. Each electrode is implanted 2.5 mm into 
the perilymphatic space of the semicircular canal adjacent to the ampullary nerve 




It would be expected that future devices will meet the existing basic require-
ments which include wearing comfort, cosmetic appeal, long battery life and 
customizable frequency-cum-level dependent gains for ideal hearing rehabilitation. 
There is extensive ongoing research in different aspects of hearing technology, some 
of which are described here. The micro-electrical–mechanical systems (MEMS) 
microphone allows for a further reduction in size as well as the possibility of multi-
ple microphones on a single device. This will be very useful for noisy environments 
for selecting a target source while rejecting other competing sounds thus improving 
directionality of the hearing device [34]. Silicon microfabrication of microphones 
making them more sensitive and with lower thermal noise was inspired by the ears 
of the parasitoid fly, Ormia ochracea and is another unique approach [35]. As the 
size of the microphone progressively reduces, self-calibrating devices are likely 
to become more common in the future. Such systems can help in achieving target 
frequency-and-level dependent gains at the initial fitting and can greatly speed 
up the initial fitting process. Initiation of the hearing device could itself trigger a 
self-adjustment procedure to ensure the device overcomes daily variations [36]. 
DSPs have progressively shrunk in size and power requirement which together 
with improvements in battery technology will contribute to increased intervals 
between battery recharging. Developments in both battery chemistry and internal 
components such has anodes will likely result in longer battery life, faster recharg-
ing, smaller size and increased voltage that will enable increased dynamic range and 
DSP processor speed [36].
Bluetooth is one such technology that hearing device manufacturers are increas-
ingly making available in their devices. This makes the hearing device compatible 
with any Bluetooth enabled technology across manufacturers allowing for hands-
free usage of phone and other sound devices. Future hearing devices may contain 
sensors already existent in smart watches and other wearable devices which may 
collect information and present it via an auditory speech signal tailored to the 
wearer. There is evidence that auditory evoked electrical responses change depend-
ing on which sound source an individual is attending to [37]. This has been referred 
to as cognitively controlled hearing aids and research is ongoing in this field at 
present. The possibilities for improving the bone conduction device in the future 
are endless. A better housing design and improved transducer technology can 
improve conventional BCDs. This would be a significant advantage since they are 
non-invasive and a lower-cost alternative. Expanding surgical criteria to children 
below a certain age with smaller devices would likely offer them better hearing at 
a younger age and improved socio-linguistic development. Development of more 
patient optimized and powerful transducers will expand current indications for 
implantation.
A variety of approaches to regeneration or repair of auditory sensory and related 
structures are being investigated to restore hearing. Future hearing devices may 
be developed consisting of an acoustic hearing aid and a linked implanted compo-
nent capable of eluting chemicals or signals for enhancement of this regenerative 
process. Drug delivery would be enabled through the implant, to preserve neurons 
or even promote the growth of neurites (toward the electrode array) from existing 
neurons or regeneration of neurons and associated structures [38, 39]. In 2002, the 
Free Electron Laser was used to conduct initial experiments on optical stimula-
tion of a peripheral nerve [40]. This concept was later transferred to the cochlea 
and stimulation units have been further miniaturized and an implantable unit for 
stimulation in cat models is currently under work [41]. Necessary safety studies 
are underway that has led to the development of an optogenetic implant unit that 
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is being used in clinical trials. The feasibility of supplementing the ABI array of 
surface electrodes with penetrating microstimulating electrodes has been dem-
onstrated in animal studies and human trials involving using this combination is 
currently ongoing. The initial results of the first AMI patients have been encourag-
ing in terms of the ability to implant the array into the auditory midbrain safely and 
to restore some hearing function. Future work in this area will needed to overcome 
the primary limitation of midbrain stimulation which is optimal placement of the 
electrode array. Research is also currently underway on creating a totally implant-
able vestibular implant in which all the components of the implant could be inter-
nalized. Advances in miniaturization, microelectromechanical systems (MEMS), 
nanotechnology, battery technology and circuit energy efficiency could help realize 
this goal. A vestibular brainstem implant could prove helpful for bilateral vestibular 
hypofunction and such a device could be potentially combined with an auditory 
brainstem device [29].
Thus, there are new development efforts in this field that will either signifi-
cantly improve prosthetic performance or change the face of auditory prosthesis 
 altogether. There is also the possibility that auditory prostheses will be integrated 
with other peripheral and central prostheses (eg. vestibular and deep brain 
implants) to treat not just one symptom but to address its whole spectrum. Finally, 
the progress in neuroscience, particularly in non-invasive brain monitoring 
will allow a full account of individual variability in both the optimization & the 
 performance of prosthetic hearing devices.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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